导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.29% | 2565/4773 |
| 近一周 | -1.60% | 573/5462 |
| 近一月 | 1.88% | 303/5421 |
| 近一季 | -3.30% | 1389/5209 |
| 近半年 | -4.94% | 2675/4920 |
| 近一年 | -1.50% | 2880/4366 |
| 近两年 | 41.13% | 1835/2954 |
| 近三年 | 39.80% | 729/2253 |
| 成立以来 | 36.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.07% 1647/4961 |
-8.60% 3901/5312 |
- - |
- - |
| 2025 | 16.34% 2463/4813 |
4.08% 998/3635 |
5.32% 609/4076 |
3.36% 3749/4524 |
2.68% 881/4813 |
| 2024 | 29.49% 129/3463 |
5.17% 397/2808 |
10.41% 38/3014 |
10.99% 2570/3129 |
0.48% 1204/3463 |
| 2023 | -0.06% 431/2656 |
4.04% 1062/2280 |
2.53% 134/2385 |
-1.44% 520/2515 |
-4.93% 1213/2655 |
| 2022 | -2.36% 55/2207 |
2.50% 52/1919 |
0.25% 1570/2016 |
-11.87% 601/2113 |
7.81% 289/2208 |
| 2021 | 3.43% 611/1822 |
11.39% 25/1255 |
-3.09% 1236/1330 |
1.47% 449/1466 |
-5.58% 1520/1822 |
| 2020 | -15.05% 1001/1250 |
-13.69% 936/1028 |
-3.13% 1038/1067 |
-2.48% 1075/1164 |
4.19% 857/1184 |
| 2019 | - - |
- - |
- - |
-5.35% 792/850 |
5.40% 722/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华宝沪港深价值指数C VS. 长安沪深300非周期A(740101) |